Atara Biotherapeutics vs TScan Therapeutics
ATRA and TCRX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ATRA and TCRX compare
Atara Biotherapeutics is the larger company, worth 6.4 times as much as TScan Therapeutics ($65.2M against $10.2M).
TScan Therapeutics grew revenue faster over the last twelve months (2.2% versus −96.7% for Atara Biotherapeutics).
Atara Biotherapeutics keeps more of each dollar of sales as profit, with a net margin of −269% compared with −1655% at TScan Therapeutics.
TScan Therapeutics scores higher on the StockData Score (4 against 3 for Atara Biotherapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ATRA | TCRX |
|---|---|---|
| Size and price | ||
| Market cap | $65.2M | $10.2M |
| Share price | $6.50 | $0.151 |
| Change, 1 year | −52.8% | −86.3% |
| Change, 5 years | −98.5% | −98.3% |
| Beta (5Y) | 1.99 | 2.15 |
| Employees | 14 | 142 |
| StockData Score | ||
| Total score | 3 | 4 (better) |
| Valuation score | 0 | 3 (better) |
| Growth score | 1 (better) | 0 |
| Performance score | 1 (better) | 0 |
| Health score | 1 | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 10.5× | 1.4× (better) |
| P/B | – | 0.1× |
| FCF yield | – | −1157% |
| Fair value | – | $1.36 |
| Margin of safety | – | 88.9% |
| Growth | ||
| Revenue growth (TTM) | −96.7% | 2.2% (better) |
| Revenue growth, 5Y average | – | 56.9% |
| Net income growth (TTM) | −388% | – |
| Profitability | ||
| Operating margin | −230% (better) | −1695% |
| Net margin | −269% (better) | −1655% |
| FCF margin | – | −1666% |
| Return on equity | – | −95.8% |
| Financial health | ||
| Debt / equity | – | 0.47 |
| Interest coverage | −5.0× (better) | −43.2× |
| Current ratio | 1.98 | 3.37 (better) |
| Altman Z-score | −136.12 | −6.31 (better) |
| Piotroski F-score | 5 (better) | 2 |
| Dividends and buybacks | ||
| Buyback yield | −14.2% | – |
| Shareholder yield | −14.2% | 0.00% (better) |
| Ownership | ||
| Held by institutions | 44.5% | 53.5% |
| Held by insiders | 55.5% | 32.8% |
| Insider net buying, 12 months | $2.0M (better) | $146K |
| Short interest, % of float | 6.6% | 4.4% |
Go deeper
- ATRA stock overview
- ATRA income statement
- ATRA valuation and score
- TCRX stock overview
- TCRX income statement
- TCRX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.